Developer docs
API playgroundTry for free, no card

Search company profiles

Viome Life Sciences

Full company profile

uuid0006lqy

Namestring
Viome Life Sciences
Legal namestring
Viome Life Sciences, Inc.
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBellevue, United States
HQ citystring
Bellevue
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
at-home microbiome testing, RNA sequencing diagnostics, precision nutrition analysis, metatranscriptomics health platform, personalized supplements recommendations
Industry3 codes
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Personalized Health Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1At-home Testing Kits
TypeSubscription Recurring
Description

Viome generates revenue through direct-to-consumer at-home microbiome and gene expression test kits. Customers purchase tests and receive personalized dietary and supplementation recommendations based on gut, oral, and cellular health analysis.

viomepro.com
2Precision Health Testing (Viome Pro)
TypeSubscription Recurring
Description

B2B revenue from healthcare providers who order comprehensive molecular health tests for their patients through integrated practice management tools.

viomepro.com
3Supplements/Personalized Nutrition Products
TypeSubscription Recurring
Description

Revenue from personalized supplement recommendations and products upsold to customers based on their test results. The review notes aggressive supplement upselling as part of the business model.

mynucleus.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
Pricing details1 tier
1Full Body Intelligence Test
ModelSubscriptionBilling cadenceAnnual
Notes

Viome is among the most expensive at-home microbiome test providers

mynucleus.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 5 records shown
1Viome Pro
Description

Precision health solutions for healthcare providers including Viome Precision Health PRO, Gut Health PRO, and Oral Health Pro molecular tests.

viomepro.com
+4 more records
Core offering1 text field

Viome Life Sciences provides at-home microbiome and gene expression tests that use metatranscriptomic RNA sequencing combined with an AI-driven recommendation engine to deliver personalized dietary, supplementation, and precision health insights. Through its Viome Pro channel, it offers healthcare providers molecular health tests (Precision Health PRO, Gut Health PRO, Oral Health Pro) for preventive care and early disease detection, including the only test for oral and throat cancer using molecular analysis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Real-world evidence analysis of over 10,000 relevant biological data points per person
+2 more records
Product overview1 text field

Viome Life Sciences offers a platform-plus-modules architecture centered on RNA sequencing and AI-powered molecular health analysis. The core offerings include Viome® Precision Health PRO (comprehensive cellular and microbiome analysis), Viome® Gut Health PRO (gut-focused analysis), and Viome® Oral Health Pro (oral microbiome and cancer detection), all powered by proprietary RNA sequencing technology and advanced AI. The Full Body Intelligence Test serves as the consumer-facing at-home testing product, while the acquired Naring Health Inc. brand reinforces the personalized health solutions portfolio.

Product and service5 records
1Viome Precision Health PRO
CategoryMolecular Health Test
Description

Comprehensive cellular health and microbiome analysis with RNA and AI technologies that provides healthcare providers with 360-degree multi-system analysis, showing root causes and associated risk factors of chronic diseases, along with longevity assessment and precision nutrition recommendations based on over 10,000 biological data points per person.

2Viome Gut Health PRO
CategoryMolecular Health Test
Description

Gut-focused molecular analysis for healthcare providers showing root causes and associated factors for gastrointestinal diseases, including data-driven analysis of microbiome functional pathways and precision nutrition and treatment recommendations for chronic gastrointestinal conditions.

3Viome Oral Health Pro
CategoryMolecular Health Test
Description

Oral microbiome molecular analysis test for healthcare providers that detects oral and throat cancer early, enhances periodontal care with objective molecular insights, and identifies oral-systemic health associations through deep molecular analysis.

4Full Body Intelligence Test
CategoryAt-Home Health Test
Description

AI-driven at-home test for consumers that uses RNA sequencing from stool, saliva, and blood samples to detect inflammation, microbial imbalance, and cellular dysfunction, providing personalized dietary and supplementation recommendations based on a decade of research and proprietary technology.

5Personalized Supplement Recommendations and Products
CategoryPersonalized Nutrition
Description

Personalized dietary supplements and nutrition products recommended to customers based on their individual test results, representing a recurring revenue stream tied to at-home test purchases.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-01
Description

Viome Life Sciences Inc. acquired Naring Health Inc. in November 2023 to strengthen its personalized health solutions offerings. This acquisition reinforced Viome's leadership in personalized health solutions within the growing personalized nutrition and supplements market.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

ZOE is a direct competitor in at-home microbiome and personalized nutrition, combining stool metagenomics with blood and CGM data to deliver dietary recommendations. It competes head-to-head with Viome on the DTC Full Body Intelligence value proposition and target consumer.

TypeDirect peer
Description

Thorne offers personalized supplement products and at-home health testing, closely overlapping with Viome's test-plus-supplement bundled model and serving similar health-conscious consumer and practitioner segments.

TypeDirect peer
Description

InsideTracker provides at-home blood biomarker analysis with AI-driven personalized nutrition and supplement recommendations, competing directly with Viome on the actionability of molecular health insights for longevity-focused consumers.

TypeDirect peer
Description

DayTwo is a microbiome-based personalized nutrition company offering gut-driven glucose and dietary recommendations. It is a direct competitor in the microbiome-to-nutrition prescription use case that Viome's Gut Health PRO addresses.

5Function Health
TypeEmerging player
Description

Function Health sells comprehensive at-home lab panels and personalized insights to preventive-health consumers, overlapping with Viome's Full Body Intelligence Test on longitudinal biomarker testing and consumer subscription model.

TypeBroad incumbent
Description

23andMe is an established consumer genetic testing and health insights platform with a large installed base, overlapping with Viome on at-home molecular health insights and DTC preventive positioning, but using DNA rather than RNA methodology.

TypeRegional player
Description

Atlas Biomed offers microbiome and DNA testing with personalized health recommendations primarily to European consumers, mirroring Viome's DTC test-plus-recommendation model in a different geography.

8Cerascreen
TypeRegional player
Description

Cerascreen sells a broad portfolio of at-home biomarker and microbiome tests across Europe, competing with Viome on the consumer testing value proposition in non-US markets at typically lower price points.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Viome Life Sciences

Personalized Health Diagnosticsviomelifesciences.com

Viome Life Sciences firmographics

Firmographics
Name
Viome Life Sciences
Legal name
Viome Life Sciences, Inc.
Website
https://viomelifesciences.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Viome Life Sciences industry classification

Industry
Product category
Personalized Health Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • At-home microbiome testing
  • RNA sequencing diagnostics
  • Precision nutrition analysis
  • Metatranscriptomics health platform
  • Personalized supplements recommendations

Where Viome Life Sciences is headquartered

Location

Headquarters

HQ city
Bellevue
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Viome Life Sciences business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. At-home Testing Kits: Viome generates revenue through direct-to-consumer at-home microbiome and gene expression test kits. Customers purchase tests and receive personalized dietary and supplementation recommendations based on gut, oral, and cellular health analysis.
  2. Precision Health Testing (Viome Pro): B2B revenue from healthcare providers who order comprehensive molecular health tests for their patients through integrated practice management tools.
  3. Supplements/Personalized Nutrition Products: Revenue from personalized supplement recommendations and products upsold to customers based on their test results. The review notes aggressive supplement upselling as part of the business model.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualFull Body Intelligence Test

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Viome Life Sciences product offering

Product offering

Core offering

Viome Life Sciences provides at-home microbiome and gene expression tests that use metatranscriptomic RNA sequencing combined with an AI-driven recommendation engine to deliver personalized dietary, supplementation, and precision health insights. Through its Viome Pro channel, it offers healthcare providers molecular health tests (Precision Health PRO, Gut Health PRO, Oral Health Pro) for preventive care and early disease detection, including the only test for oral and throat cancer using molecular analysis.

Product overview

Viome Life Sciences offers a platform-plus-modules architecture centered on RNA sequencing and AI-powered molecular health analysis. The core offerings include Viome® Precision Health PRO (comprehensive cellular and microbiome analysis), Viome® Gut Health PRO (gut-focused analysis), and Viome® Oral Health Pro (oral microbiome and cancer detection), all powered by proprietary RNA sequencing technology and advanced AI. The Full Body Intelligence Test serves as the consumer-facing at-home testing product, while the acquired Naring Health Inc. brand reinforces the personalized health solutions portfolio.

Differentiator

Problem solved

Functional benefit

Brands

  • Viome Pro: Precision health solutions for healthcare providers including Viome Precision Health PRO, Gut Health PRO, and Oral Health Pro molecular tests.
  • Viome Precision Health PRO
  • Gut Health PRO
  • Oral Health Pro
  • Full Body Intelligence

Products and services

  • Viome Precision Health PRO Comprehensive cellular health and microbiome analysis with RNA and AI technologies that provides healthcare providers with 360-degree multi-system analysis, showing root causes and associated risk factors of chronic diseases, along with longevity assessment and precision nutrition recommendations based on over 10,000 biological data points per person.
  • Viome Gut Health PRO Gut-focused molecular analysis for healthcare providers showing root causes and associated factors for gastrointestinal diseases, including data-driven analysis of microbiome functional pathways and precision nutrition and treatment recommendations for chronic gastrointestinal conditions.
  • Viome Oral Health Pro Oral microbiome molecular analysis test for healthcare providers that detects oral and throat cancer early, enhances periodontal care with objective molecular insights, and identifies oral-systemic health associations through deep molecular analysis.
  • Full Body Intelligence Test AI-driven at-home test for consumers that uses RNA sequencing from stool, saliva, and blood samples to detect inflammation, microbial imbalance, and cellular dysfunction, providing personalized dietary and supplementation recommendations based on a decade of research and proprietary technology.
  • Personalized Supplement Recommendations and Products Personalized dietary supplements and nutrition products recommended to customers based on their individual test results, representing a recurring revenue stream tied to at-home test purchases.

Quantifiable outcome

  • Real-world evidence analysis of over 10,000 relevant biological data points per person
  • +2 more outcomes

Companies that use Viome Life Sciences

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Viome Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Viome Life Sciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Naring Health Inc.coreStrategic or Co-development Partner · 1 November 2023Viome Life Sciences Inc. acquired Naring Health Inc. in November 2023 to strengthen its personalized health solutions offerings. This acquisition reinforced Viome's leadership in personalized health solutions within the growing personalized nutrition and supplements market.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Viome Life Sciences competitors and assessment

Company assessment

Direct peers

  • ZOE: ZOE is a direct competitor in at-home microbiome and personalized nutrition, combining stool metagenomics with blood and CGM data to deliver dietary recommendations. It competes head-to-head with Viome on the DTC Full Body Intelligence value proposition and target consumer.
  • Thorne HealthTech: Thorne offers personalized supplement products and at-home health testing, closely overlapping with Viome's test-plus-supplement bundled model and serving similar health-conscious consumer and practitioner segments.
  • InsideTracker: InsideTracker provides at-home blood biomarker analysis with AI-driven personalized nutrition and supplement recommendations, competing directly with Viome on the actionability of molecular health insights for longevity-focused consumers.
  • DayTwo: DayTwo is a microbiome-based personalized nutrition company offering gut-driven glucose and dietary recommendations. It is a direct competitor in the microbiome-to-nutrition prescription use case that Viome's Gut Health PRO addresses.

Emerging players

  • Function Health: Function Health sells comprehensive at-home lab panels and personalized insights to preventive-health consumers, overlapping with Viome's Full Body Intelligence Test on longitudinal biomarker testing and consumer subscription model.

Broad incumbents

  • 23andMe: 23andMe is an established consumer genetic testing and health insights platform with a large installed base, overlapping with Viome on at-home molecular health insights and DTC preventive positioning, but using DNA rather than RNA methodology.

Regional players

  • Atlas Biomed: Atlas Biomed offers microbiome and DNA testing with personalized health recommendations primarily to European consumers, mirroring Viome's DTC test-plus-recommendation model in a different geography.
  • Cerascreen: Cerascreen sells a broad portfolio of at-home biomarker and microbiome tests across Europe, competing with Viome on the consumer testing value proposition in non-US markets at typically lower price points.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Viome Life Sciences social profiles

Digital presence

Viome Life Sciences compliance and trust

Trust signal

Compliance1 record

Viome Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Viome Life Sciences leadership team

Management profile

Number of profiles

Profiles1 record

Viome Life Sciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Viome Life Sciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Viome Life Sciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viome Life Sciences

What does Viome Life Sciences do?

Viome Life Sciences provides at-home microbiome and gene expression tests that use metatranscriptomic RNA sequencing combined with an AI-driven recommendation engine to deliver personalized dietary, supplementation, and precision health insights. Through its Viome Pro channel, it offers healthcare providers molecular health tests (Precision Health PRO, Gut Health PRO, Oral Health Pro) for preventive care and early disease detection, including the only test for oral and throat cancer using molecular analysis.

Is Viome Life Sciences a public or private company?

Viome Life Sciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Viome Life Sciences founded?

Viome Life Sciences was founded in 2016. It employs 11 to 50 people.

Where is Viome Life Sciences based?

Viome Life Sciences is headquartered in Bellevue, United States, in the North America region.

How does Viome Life Sciences make money?

Three revenue lines are on record. At-home Testing Kits are the primary driver. The others are precision Health Testing (Viome Pro) and supplements/Personalized Nutrition Products.

Who are Viome Life Sciences's main competitors?

Direct peers on record are ZOE, Thorne HealthTech, InsideTracker and DayTwo. Function Health is listed as an emerging player. 23andMe is listed as a broad incumbent. Regional players are Atlas Biomed and Cerascreen.

Does Viome Life Sciences have an API?

No public API is recorded for Viome Life Sciences.

What industry is Viome Life Sciences in?

Viome Life Sciences's product category is Personalized Health Diagnostics. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device NetworkViome PRO introduces blood test for pancreatic cancerViome PRO launched CancerDetect Pancreatic, a physician-ordered blood test for pancreatic ductal adenocarcinoma in adults 50 and older. In blinded validation, it achieved 90% specificity and detected 86% of stage I and II cancers, but is not FDA cleared. Fountain Life will be the first provider.Longevity.TechnologyIs blood filtering the new wellness flex?Viome Life Sciences has acquired Circulate Health, combining its precision diagnostics with therapeutic plasma exchange protocols to create a full-stack longevity platform. The acquisition aims to close the loop between measuring biological markers and providing clinical interventions, highlighted by data showing reductions in microplastics and biological age among patients.HIT ConsultantViome Life Sciences Acquires Circulate Health to Launch Viome Professional Clinical GroupViome Life Sciences has acquired Circulate Health to launch the Viome Professional Clinical Group, integrating Circulate’s outpatient therapeutic plasma exchange protocols with Viome’s molecular diagnostic platform. The acquisition establishes an integrated operational model allowing care teams to measure biological markers, administer targeted therapies, and re-test outcomes, led by former Circulate CEO Dr. Brad Younggren.PR NewswireViome Acquires Circulate Health, Closing the Loop Between Early Diagnostics, Precision Nutrition, and TreatmentViome Life Sciences acquired Circulate Health, a therapeutic plasma exchange provider, to combine diagnostics with physician-guided treatment. The deal unites Viome's precision nutrition platform with Circulate's nationwide clinic network, aiming to deliver measurable health outcomes. Dr. Brad Younggren will lead the new Viome PRO clinical group.Global InformationSmart In Vitro Diagnostics. Artificial Intelligence for IVD Markets By Application, By Technology, By Product and By User. With Executive and Consultant Guides 2026-2030Howe Sound Research has published a market research report on AI-enabled in vitro diagnostics, projecting significant growth driven by increasing diagnostic data complexity, precision medicine expansion, and adoption of digital pathology across clinical chemistry, molecular diagnostics, pathology, genomics, and point-of-care testing. The report, covering 2026-2030 with breakouts for 18 countries and 4 regions, identifies key players including diagnostic companies, software developers, and digital health firms competing on algorithm performance, data quality, and regulatory approval status. Recent developments cited include multiple financing rounds (Ataraxis AI, Viome Life Sciences raising $86.5M), technology licensing agreements (Myriad Genetics), investment partnerships (Danaher with AI firm I), regulatory clearances (Becton Dickinson, Cardio Dx), and strategic alliances across the digital pathology ecosystem.GlobeNewswirePersonalized Nutrition and Supplements Market Analysis Report 2026: $24.52 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe personalized nutrition and supplements market is projected to grow from $13.39 billion in 2025 to $24.52 billion by 2030, driven by increased health awareness, genomics integration, and subscription models. Key developments include technological innovations and an acquisition by Viome Life Sciences Inc. to strengthen personalized health solutions, with North America leading the market geographically.YahooPersonalized Nutrition and Supplements Market Analysis Report 2026: $24.52 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FResearchAndMarkets.com published a market report projecting the personalized nutrition and supplements market to grow from $13.39 billion in 2025 to $24.52 billion by 2030, representing a 12.8% CAGR. The report identifies rising consumer health awareness, genomics integration, and expansion of subscription-based models as key growth drivers. A notable transaction in the sector is Viome Life Sciences Inc.'s acquisition of Naring Health Inc. in November 2023 to strengthen its personalized health solutions offerings.openPR.comAI-Driven Personalized Nutrition Market: The Science of Eating for Your Unique BiologyMarket Research Corridor published a market research report on the AI-Driven Personalized Nutrition Market, which is undergoing a paradigm shift from generic dietary guidelines to data-driven precision nutrition using genetic markers, gut microbiome composition, blood biomarkers, and metabolic responses. The market is segmented by measurement type (gut microbiome, genetic, blood/biomarker, metabolic monitoring), application (weight management, chronic disease, sports nutrition, immune health), and end user (DTC, wellness centers, hospitals, corporate wellness), with North America currently leading while Asia-Pacific emerges as the fastest-growing region. Key industry players include ZOE, Viome Life Sciences, DayTwo, InsideTracker, Noom, Nestlé Health Science, Bayer, Abbott, and DSM, as the sector navigates challenges including high costs, scientific skepticism, regulatory uncertainty, and data privacy concerns while pursuing opportunities in corporate wellness integration and insurance reimbursement.Nova One AdvisorPersonalized Retail Nutrition And Wellness Market SizeThe global personalized retail nutrition and wellness market was valued at USD 3.65 billion in 2023 and is projected to reach USD 15.04 billion by 2033, growing at a CAGR of 15.21%, with North America accounting for the largest regional share of 41.43% and repeat recommendations representing the leading segment at 46.36%. Key recent developments include Nestlé Health Science launching a DNA-based personalized nutrition platform in partnership with Nutrigenomix, Viome Life Sciences receiving FDA breakthrough device designation for its AI-driven microbiome diagnostic test, and Bayer-owned Care/of integrating continuous glucose monitoring into its subscription offerings. The market is being driven by consumer demand for preventative wellness and digital health integration, though high costs and accessibility barriers remain significant restraints on widespread adoption.NextmscPersonalized Nutrition Market ShareNext Move Strategy Consulting released a market research report projecting the global personalized nutrition market to grow from USD 14.77 billion in 2024 to USD 35.42 billion by 2030, driven by rising health awareness and disposable income. Key industry players such as Viome Life Sciences Inc., Aeroflow Inc., and Segterra Inc. are expanding their offerings through product launches and acquisitions to capture market share.